Overview
Anemia is a prevalent and distressing complication in patients with malignant neoplastic diseases, significantly impacting their quality of life and functional status. Despite its high prevalence and clinical importance, patients with hematological malignancies often face barriers to accessing palliative care services, which can mitigate symptoms and improve overall well-being. Studies indicate that only about 54% of patients with malignant hematological diagnoses utilize palliative care services, with notable disparities observed among Hispanic (47%), African American (49%), Medicaid-insured (48%), and those admitted to smaller or rural hospitals (52% and 47%, respectively) [PMID:38803232]. These disparities underscore the need for targeted interventions to ensure equitable access to palliative care, particularly for vulnerable populations. Early integration of palliative care can alleviate severe symptoms and reduce the need for hospitalizations or emergency department visits, thereby improving end-of-life experiences [PMID:30808629].
Pathophysiology
Anemia in cancer patients arises from multifaceted pathophysiological mechanisms, primarily driven by the systemic inflammatory response characteristic of malignancies. Cytokines such as tumor necrosis factor-alpha (TNF-α), transforming growth factor-beta (TGF-β), interleukin-1 (IL-1), interleukin-6 (IL-6), and interferon-γ play pivotal roles in disrupting normal erythropoiesis. These cytokines interfere with the production of erythrocytes by suppressing the activity of erythropoietin (EPO) and inhibiting the proliferation and differentiation of erythroid progenitor cells in the bone marrow [PMID:31387568]. Additionally, cancer treatments like chemotherapy and radiation therapy can directly damage bone marrow, further exacerbating anemia. Nutritional deficiencies, particularly iron, vitamin B12, and folate deficiencies, also contribute significantly to the development and persistence of anemia in these patients [PMID:27637832].
Epidemiology
The epidemiology of anemia in malignant neoplastic diseases reveals significant variations in its prevalence and management across different patient subgroups. Among 49,720 weighted cases of patients with malignant hematological diagnoses from 2016 to 2019, only 54% utilized palliative care services, highlighting disparities in care access [PMID:38803232]. Genitourinary malignancies, hematological malignancies, and patients undergoing active therapy for advanced cancer were more likely to require red blood cell (RBC) transfusions, with hematological malignancies showing the strongest association (p < 0.001) [PMID:39397730]. Nutritional status further complicates the clinical picture, with malnutrition and muscle wasting being common and significantly impacting clinical outcomes [PMID:27637832]. Wide variations in dietary intake, including energy and protein consumption, underscore the nutritional vulnerability of these patients, with intakes ranging from 4 to 53 kcal/kg/day and 0.2 to 2.7 g/kg/day, respectively [PMID:17093170]. These factors collectively contribute to the complexity of managing anemia in cancer patients.
Clinical Presentation
Anemia in patients with malignant neoplastic diseases manifests through a constellation of symptoms that profoundly affect their quality of life and functional capacity. Fatigue, a hallmark symptom, is frequently reported and significantly impacts daily activities and overall well-being [PMID:31387568]. The fatigue assessment tools, such as the Brief Fatigue Inventory and FACT-Fatigue subscale, have been validated and are well-received in clinical settings, demonstrating both statistical and clinically significant improvements post-transfusion in anemic cancer patients [PMID:20973677]. Additionally, anemia contributes to other symptoms like weakness, dyspnea, and cognitive impairment, which can exacerbate the overall burden of disease. Nutritional deficiencies and muscle wasting further compound these symptoms, necessitating comprehensive nutritional assessments and interventions [PMID:39278864]. Regular screening for malnutrition risk is crucial for all cancer patients, except those in end-of-life care, to proactively manage these symptoms [PMID:27637832].
Diagnosis
Diagnosing anemia in patients with malignant neoplastic diseases involves a multifaceted approach, integrating clinical symptoms with laboratory findings. Common laboratory indicators include low hemoglobin levels, reduced hematocrit, and altered iron metabolism markers. Independent predictors of 30-day mortality in these patients include elevated serum calcium levels, abnormal neutrophil counts, increased urea levels, and elevated glutamic oxaloacetic transaminase (GOT) levels [PMID:37164964]. These biomarkers, along with clinical judgment, help in assessing the severity and underlying causes of anemia. Prognostic tools, such as nomograms incorporating serum calcium, neutrophil count, urea, and GOT, have shown utility in predicting short-term survival, aiding clinicians in tailoring management strategies [PMID:37164964]. However, the reliance on objective symptom scales for follow-up remains suboptimal, with only 28% of physicians using such scales post-transfusion, indicating a gap in standardized clinical practices [PMID:30896276].
Management
The management of anemia in malignant neoplastic diseases requires a holistic approach, balancing symptomatic relief with the broader context of patient well-being and nutritional status. Transfusion decisions should prioritize improving functional status and quality of life over rigid hemoglobin thresholds, aiming to alleviate symptoms like fatigue and lethargy [PMID:31387568]. Recommended hemoglobin thresholds for transfusion in palliative settings typically range from 7-9 g/dL for restricted transfusion to 10-12 g/dL for liberal transfusion, emphasizing clinical judgment [PMID:31387568]. Nutritional interventions play a critical role, with evidence suggesting that a diet rich in fruits and vegetables can positively influence plasma carotenoid levels, potentially mitigating inflammation and other chronic conditions [PMID:35956359]. Registered dietitians are essential in providing personalized nutritional guidance, addressing deficiencies, and integrating nutritional support with exercise training to combat malnutrition and muscle wasting [PMID:27637832]. Home palliative care services, including domiciliary blood transfusions, have shown benefits in symptom management and quality of life, aligning with patient preferences for care in familiar settings [PMID:18655644].
Complications
Managing anemia in cancer patients involves addressing potential complications associated with both the underlying disease and therapeutic interventions. Adverse reactions to transfusions, including allergic reactions and transfusion-related immunomodulation, are significant concerns, necessitating vigilant monitoring [PMID:30896276]. Nutritional interventions, particularly parenteral nutrition, can be effective but carry risks of complications such as infections and metabolic imbalances. A study found that approximately 50% of patients receiving home total parenteral nutrition (TPN) did not experience severe complications, highlighting its feasibility in palliative care settings [PMID:15112279]. Additionally, the timing of transfusions, with half of patients receiving them less than a month before death, underscores the importance of careful consideration of transfusion benefits and risks in end-of-life care [PMID:39397730].
Prognosis & Follow-up
The prognosis of anemia in malignant neoplastic diseases is closely tied to the overall clinical status and response to interventions. While blood transfusions can provide rapid symptomatic relief, long-term benefits are inconsistent, emphasizing the need for individualized follow-up and reassessment [PMID:31387568]. Prognostic tools, such as nomograms incorporating serum calcium, neutrophil count, urea, and GOT, offer valuable insights into short-term survival predictions, aiding in clinical decision-making [PMID:37164964]. The duration of home care and the timing of last transfusions to death show significant correlations, indicating potential prognostic implications [PMID:39397730]. Regular reassessment of patients for symptomatic improvement post-transfusion, ideally using validated fatigue scales, is crucial but remains underutilized [PMID:30896276]. Accurate prognostic tools, such as PPI, LPS, and PaP, provide comparable discriminative abilities for mortality at various time points, particularly for intermediate survival periods (14-59 days), enhancing clinical management [PMID:38692458].
Special Populations
Certain patient subgroups, including older adults and those from lower socioeconomic backgrounds, face unique challenges in managing anemia due to malignant neoplastic diseases. Older women from disadvantaged neighborhoods exhibit lower serum carotenoid concentrations, indicating potential disparities in nutritional support needs [PMID:35956359]. Palliative care utilization increases with age, reaching 58% among those 80 years and older, suggesting a growing recognition of its benefits in advanced age groups [PMID:38803232]. However, the appropriateness of RBC transfusions in these populations requires careful consideration, especially given the frequent late-life administration of transfusions [PMID:39397730]. Tailored nutritional guidance and support from dietitians are essential in addressing the specific challenges faced by these patients, including managing anemia through targeted interventions [PMID:39278864]. Cancer survivors are advised to maintain regular physical activity and a prudent diet to support recovery and overall health, recognizing the long-term implications of nutritional status and physical well-being [PMID:27637832].
Key Recommendations
References
1 Zasowska-Nowak A, Nowak PJ, Cialkowska-Rysz A. Carotenoids in Palliative Care-Is There Any Benefit from Carotenoid Supplementation in the Adjuvant Treatment of Cancer-Related Symptoms?. Nutrients 2022. link 2 Timilsina S, Karki S, Timalsina S, Gautam A, Sharma S. Does packed red cell transfusion provide symptomatic benefits to cancer palliative patients?: a longitudinal study from a single private oncology center in Nepal. BMC palliative care 2019. link 3 Hsieh TC, Yeo YH, Zou G, Zhou C, Ash A. Disparities in Palliative Care Use for Patients With Blood Cancer Who Died in the Hospital. The American journal of hospice & palliative care 2025. link 4 Ostan R, Varani S, Yaaqovy AD, Patrignani M, Pannuti R, Bruera E et al.. Red Blood Cell Transfusions in Patients with Advanced Cancer Receiving Home Palliative Care. Journal of palliative medicine 2024. link 5 Soares CH, Beuren AG, Friedrich HJ, Gabrielli CP, Stefani GP, Steemburgo T. The Importance of Nutrition in Cancer Care: A Narrative Review. Current nutrition reports 2024. link 6 Yuasa N, Kawai N, Takamizawa J. Comparison of Prognostic Abilities of Palliative Prognostic Index, Laboratory Prognostic Score, and Palliative Prognostic Score. Journal of pain and symptom management 2024. link 7 Fan R, Li X, Tan Y, Yang S, Bu X, Chen Y et al.. Development of a prognostic nomogram based on objective blood test data for patients with advanced cancer undergoing palliative care. Annals of palliative medicine 2023. link 8 Tricou C, Munier S, Phan-Hoang N, Albarracin D, Perceau-Chambard É, Filbet M. Haematologists and palliative care: a multicentric qualitative study. BMJ supportive & palliative care 2022. link 9 Chin-Yee N, Taylor J, Downar J, Tanuseputro P, Saidenberg E. Red Blood Cell Transfusion in Palliative Care: A Survey of Palliative Care Physicians. Journal of palliative medicine 2019. link 10 Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F et al.. ESPEN guidelines on nutrition in cancer patients. Clinical nutrition (Edinburgh, Scotland) 2017. link 11 Brown E, Hurlow A, Rahman A, Closs SJ, Bennett MI. Assessment of fatigue after blood transfusion in palliative care patients: a feasibility study. Journal of palliative medicine 2010. link 12 Devlin B, Agnew A. An evaluation of a domiciliary blood transfusion service for palliative care patients in Northern Ireland. Community practitioner : the journal of the Community Practitioners' & Health Visitors' Association 2008. link 13 Suh SY, Ahn HY. Lactate dehydrogenase as a prognostic factor for survival time of terminally ill cancer patients: a preliminary study. European journal of cancer (Oxford, England : 1990) 2007. link 14 Hutton JL, Martin L, Field CJ, Wismer WV, Bruera ED, Watanabe SM et al.. Dietary patterns in patients with advanced cancer: implications for anorexia-cachexia therapy. The American journal of clinical nutrition 2006. link 15 Leibovitz A, Baumoehl Y, Walach N, Kaplun V, Sigler E, Balan S et al.. Medical staff attitudes: views and positions regarding blood transfusion to terminally ill cancer patients. American journal of clinical oncology 2004. link 16 Lundholm K, Daneryd P, Bosaeus I, Körner U, Lindholm E. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function. Cancer 2004. link